Peijia Medical Co.

Peijia Medical is a medical device company focused on the development and manufacture of interventional devices for structural heart disease and cerebrovascular conditions. Their products include transcatheter aortic valve replacement (TAVR) systems, mitral and tricuspid valve repair devices, and neurovascular products for stroke treatment (per company website).

No. Peijia Medical is a publicly traded medical device company listed on the Hong Kong Stock Exchange (9996.HK). It is an operating company with its own R&D, manufacturing, and commercial operations, not an investment or family office entity.

Peijia operates as a corporate entity with a board of directors and public shareholders. It is not structured as a trust or partnership. The company reports financial results and operational updates through Hong Kong Stock Exchange filings.

Peijia focuses on structural heart disease (aortic, mitral, tricuspid valves) and cerebrovascular intervention (hemorrhagic and ischemic stroke devices). It terms this a 'heart-brain co-treatment' strategy (per company website).

Peijia is headquartered in Suzhou, China, with additional offices in Geneva, London, New York, Schwyz, Paris, Doha, and Antwerp. Its primary commercial market is China, but it maintains a global footprint for R&D and business development.

Peijia went public via an IPO on the Hong Kong Stock Exchange in May 2020. Prior to that, it likely raised private capital, but specific investors and amounts are not detailed on the company website. The company does not disclose AUM or investment-related metrics.